Research Trials

If you have any questions or are interested in participating in one of our clinical research studies, please call us at 402.955.2691 or email us at clinicaltrials@nebraskacancer.com.

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • CRB-701-02

    A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared with Investigator’s Choice of Capecitabine, Cetuximab, or Docetaxel in Participants with Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated with Platinum-based Chemotherapy and a PD-(L)1 Inhibitor

    Cancer Type: HEAD AND NECK

    Lines of Therapy: 2

    Biomarkers: PD-L1

    Phase: 3

  • AUR103-202

    A Phase 2 Study Evaluating the Efficacy and Safety of Single Agent AUR103 Calcium in Patients with Advanced, Well or Moderately differentiated Neuroendocrine Tumours (BHARAT-3)

    Cancer Type: NET

    Lines of Therapy: 2

    Biomarkers: CD47

    Phase: 2

    View Details on ClinicalTrials.gov

  • P-Trilaciclib-LSSCLC-01

    A phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with limited-stage small cell lung cancer

    Cancer Type: SCLC

    Lines of Therapy: 1

    Phase: 3

    View Details on ClinicalTrials.gov

  • INBRX-106-01-201

    A Phase 2/3 randomized study of INBRX-106 combined with pembrolizumab vs pembrolizumab as 1st line treatment for patietns with locally advanced or metastatic head and neck squamous cell carcinoma expressing PD-L1

    Cancer Type: HEAD AND NECK

    Biomarkers: PD-L1

    Phase: 2,3

    View Details on ClinicalTrials.gov

  • D763TC00001 (tropion Urothelial-04)

    A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04)

    Cancer Type: Urothelial

    Lines of Therapy: 1

    Phase: 3

  • GO45322

    A PHASE II PROSPECTIVE, OPEN-LABEL SAFETY STUDY OF INAVOLISIB AND FULVESTRANT WITH OR WITHOUT PALBOCICLIB IN PARTICIPANTS WITH PIK3CA-MUTATED HORMONE-RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER AND TYPE 2 DIABETES

    Cancer Type: BREAST

    Lines of Therapy: 2 or 3

    Biomarkers: HR+, HER2- , PIK3CA

    Phase: 2

    View Details on ClinicalTrials.gov

  • TCMCB07-01

    Optimizing Body Mass Index (BMI) with TCMCB07 in Patients with Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy

    Cancer Type: Colorectal

    Lines of Therapy: 1

    Phase: 2

    View Details on ClinicalTrials.gov

  • TER-2013-C01

    A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    Cancer Type: Solid tumor

    Biomarkers: AKT, PI3K, PTEN

    Phase: 1

    View Details on ClinicalTrials.gov

  • INBRX-106

    An Open-Label, multicenter, First in Human, Dose Escalation, Phase 1/2 Study of INBRX-106 in Subjects with locally advanced or metastatic solid tumors

    Cancer Type: NSCLC

    Lines of Therapy: 3, 2, 1

    Biomarkers: PD-L1

    Phase: 1

    View Details on ClinicalTrials.gov

  • M24-533

    Phase 2, randomized master protocol study to evaluate safety and efficacy of multiple treatment combinations with telisotuzumab adizutecan in subjects with mets colorectal cancer.

    Cancer Type: Colorectal

    Lines of Therapy: 1

    Phase: 2

    View Details on ClinicalTrials.gov

Purpose   •   Innovation   •   Relationship   •   Excellence

#caringforthegoodlife

© 2026 Nebraska Cancer Specialists  •  Privacy Policy  •  design by Chip Thompson

Meet DOT.
Skip to content